Skip to content

Chimeric IL-15 as a next-generation immunotherapeutic: preclinical assessment of efficacy and safety.

Sep 2026 · International Immunopharmacology · Vol 188, pp. 117317 · 0 citations · 41 references
Medicine

TL;DR

It is demonstrated that chimeric IL-15 induces robust antitumor immunity with improved pharmacokinetics and a favourable safety profile, supporting its further preclinical development as a next-generation cancer immunotherapeutic.

Abstract

Interleukin-15 (IL-15) is a potent immunostimulatory cytokine but is limited by rapid clearance and systemic toxicity. To overcome these limitations, our laboratory generated a chimeric IL-15 by fusing human IL-15 to the murine IgG2a Fc domain and evaluated its activity, efficacy, pharmacokinetics, and safety. The purified protein showed accurate molecular integrity determined through SDS-PAGE and Western blot. In-vitro, chimeric IL-15 induced dose-dependent activation of CD4+ and CD8+ T cells and NK cells, with increased frequencies of CD8+CD107a+ cytotoxic T cells and CD8+IFN-γ+ effector populations. In-vivo treatment resulted in time- and dose-dependent expansion of splenic cytotoxic lymphocyte subsets. Pharmacokinetic analysis demonstrated rapid distribution and a prolonged half-life of 40-53 h, while biodistribution studies confirmed widespread tissue localisation without abnormal accumulation. In syngeneic B16F10 melanoma and 4T1 breast cancer models, chimeric IL-15 significantly inhibited tumour growth and improved survival, accompanied by increased infiltration and activation of CD8+ T cells and NK cells in tumours and lymphoid tissues. Acute and subacute toxicity studies revealed no major haematological, biochemical, or histopathological abnormalities, with only transient, reversible elevations in liver enzymes at higher doses. Collectively, these findings demonstrate that chimeric IL-15 induces robust antitumor immunity with improved pharmacokinetics and a favourable safety profile, supporting its further preclinical development as a next-generation cancer immunotherapeutic.

View source

Similar papers

Open access Oct 2026

A reciprocally masked anti-CD47/IL-2 fusion protein promotes antitumor immunity and limits systemic toxicity.

Cancer immunotherapies have achieved meaningful clinical benefit but remain limited by systemic toxicities that restrict the use of potent immune modulators. CD47-targeting antibodies promote tumor cell phagocytosis but are hindered by hematologic toxicity, while IL-2 activates cytotoxic lymphocytes but induces broad,...

Elise Léchine, Laura Cons, L. Garnier et al. · 0 citations
Open access Sep 2026

αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells

This study highlights a strategy to use TIL-targeted cytokine mimetics to overcome the limitations of native cytokines and enable dose pairing with immune checkpoint blockade (ICB), offering a path toward safer and more effective cytokine immunotherapy.

Xiang-Ming Liu, Nan Li, Yu-Meng Chen et al. · 0 citations
Open access Oct 2026

The effect of a PD-1/CTLA-4 tandem scFv on T cell cytokine response under immunosuppressive conditions

Immune checkpoint blockade targeting PD-1 and CTLA-4 has shown promise in cancer immunotherapy; however, limitations such as immune resistance and toxicity from combined full-length antibodies remain. Tandem single-chain variable fragments (scFvs) offer a novel bispecific approach with potentially improved tissue p...

F. Maleki, Farhoodeh Ghaedrahmati, N. Esmaeil et al. · 0 citations
Open access Oct 2026

IL‑18 improves the expansion and functional fitness of human Vδ1 T cells for superior solid tumor immunotherapy

Human Vδ1 T cells represent promising candidates for allogeneic adoptive immunotherapy due to their MHC-independent tumor recognition and inherent tissue tropism. However, their clinical translation is hampered by their low frequency in peripheral blood and the challenge of generating sufficient functional cells...

Shun-Tian Chen, Lu-Jie Zhao, Xin-Rui Xie et al. · 0 citations
Review Open access Oct 2026

Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer

Interleukin-12 (IL-12) is a potent immunostimulatory cytokine with well-established antitumor activity, but systemic recombinant IL-12 administration has been constrained by inflammatory toxicity, high circulating cytokine peaks, and insufficient tumor-local exposure. IMNN-001 is a non-viral IL-12 gene therapy candidat...

Khursheed Anwer, Subeena Sood, Jeff Sparks et al. · 0 citations
Oct 2026

Safety of Autologous Infusion of CER T Cells in Nonhuman Primates

Cellular immunotherapies have shown great promise in the treatment of various diseases. Chimeric engulfment receptor (CER)-engineered T cells were developed to utilize the extracellular T-cell immunoglobulin and mucin domain-containing 4 (TIM-4) domain and intracellular engulfment signaling domains to target and enhanc...

K. Eichholz, A. Okoye, B. Varco-Merth et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.